S220: GLOFITAMAB INDUCES DURABLE COMPLETE REMISSIONS AND HAS FAVORABLE SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA AND ≥2 PRIOR THERAPIES: PIVOTAL PHASE II EXPANSION RESULTS - M. Dickinson; C. Carlo-Stella; F. Morschhauser; E. Bachy; P. Corradini; G. Iacoboni; C. Khan; T. Wróbel; F. Offner; M. Trněný; S.-J. Wu; G. Cartron; et al. (HemaSphere, 2022)